The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based ...

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal ...

Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.

Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

Mr Stanley, who is registered blind and was diagnosed with Bardet Biedl syndrome in 2010, worked as a factory packer for 18 years before he was taken on by The Village Bakery. The tribunal heard ...

IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or ...

MeiraGTx (MGTX) announced the U.S. Food and Drug Administration, FDA, has granted the Company Rare Pediatric Disease Designation, RPDD, to its ...